IP Library Granted Patent US 10,876,101
Granted Patent B2
US 10,876,101 · App. 15/937,840 · Granted Dec 29, 2020

CRISPR-associated (Cas) protein

Inventors: Matthew Merrill Carter (Berkeley, CA); Paul Daniel Donohoue (Berkeley, CA)
Assignee: Locanabio, Inc.
C12N9/22C12N15/11C12N15/111C12N15/1136C12N15/85C12N2310/20C12N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,876,101
App. No.
15/937,840
Granted
Dec 29, 2020
Kind
B2
Abstract

A new CRISPR-associated (Cas) protein, termed “CasM,” is described, as well as polynucleotides encoding the same and methods of using CasM for site-specific genome engineering. CasM proteins are capable of targeting and cleaving single-stranded RNA.

Claims (16)

1. A Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) nucleoprotein complex, wherein the nucleoprotein complex comprises a Cas protein selected from the group consisting of SEQ ID NO:37, SEQ ID NO:39, and SEQ ID NO:44, an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:37, an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:39, and an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:44; and a cognate nucleic acid guide comprising a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein and the cognate nucleic acid guide form the nucleoprotein complex, and wherein the nucleoprotein complex is capable of site-directed binding to a target nucleic acid sequence.

2. The Cas nucleoprotein complex of claim 1 , wherein the cognate nucleic acid guide comprises a crRNA.

3. The Cas nucleoprotein complex of claim 1 , wherein the Cas protein comprises an N- or C-terminal nuclear localization signal sequence (NLS).

4. The Cas nucleoprotein complex of claim 1 , wherein the Cas protein comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO:44.

5. The Cas nucleoprotein complex of claim 1 , wherein the cognate nucleic acid guide comprises a modified base analog.

6. A eukaryotic cell comprising the Cas nucleoprotein complex of claim 1 .

7. The eukaryotic cell of claim 6 , further comprising one or more additional Cas nucleoprotein complexes.

8. The eukaryotic cell of claim 7 , wherein the eukaryotic cell is a human cell.

9. The Cas nucleoprotein complex of claim 1 , wherein the Cas protein is catalytically active.

10. The Cas nucleoprotein complex of claim 1 , wherein the Cas protein comprises a fusion protein.

11. A Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) nucleoprotein complex, wherein the nucleoprotein complex comprises a Cas protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:39, and SEQ ID NO:44 and a cognate nucleic acid guide comprising a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein is capable of forming the nucleoprotein complex with the cognate nucleic acid guide and wherein the complex is capable of site-directed binding to a target nucleic acid sequence.

12. The Cas nucleoprotein complex of claim 11 , wherein the Cas protein comprises the amino acid sequence of SEQ ID NO: 37.

13. The Cas nucleoprotein complex of claim 11 , wherein the Cas protein comprises the amino acid sequence of SEQ ID NO: 39.

14. The Cas nucleoprotein complex of claim 11 , wherein the Cas protein comprises the amino acid sequence of SEQ ID NO: 44.

15. The Cas nucleoprotein complex of claim 4 , wherein the Cas protein comprises the amino acid sequence of SEQ ID NO: 44.

16. The Cas nucleoprotein complex of claim 1 , wherein the Cas protein is catalytically inactive.

Assignments (3)
CHANGE OF NAME Recorded Apr 1, 2021
From: LOCANA, INC.
To: LOCANABIO, INC.
Reel/Frame 055810/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: CARIBOU BIOSCIENCES, INC.
To: LOCANA, INC.
Reel/Frame 052842/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2018
From: CARTER, MATTHEW MERRILL; DONOHOUE, PAUL DANIEL
To: CARIBOU BIOSCIENCES, INC.
Reel/Frame 045406/0256 →
Continuity (3)
Provisional Application 62477494 · Mar 28, 2017
Provisional Application 62629641 · Feb 12, 2018
Related Publication 20180282715A1 · Oct 4, 2018